210 related articles for article (PubMed ID: 10411938)
41. Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) up-regulates death receptor 5 (DR5) mediated by NFkappaB activation in epithelial derived cell lines.
Shetty S; Gladden JB; Henson ES; Hu X; Villanueva J; Haney N; Gibson SB
Apoptosis; 2002 Oct; 7(5):413-20. PubMed ID: 12207174
[TBL] [Abstract][Full Text] [Related]
42. Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8.
Sprick MR; Rieser E; Stahl H; Grosse-Wilde A; Weigand MA; Walczak H
EMBO J; 2002 Sep; 21(17):4520-30. PubMed ID: 12198154
[TBL] [Abstract][Full Text] [Related]
43. Experimental study of the RV-HSV-TK/GCV suicide gene therapy system in gastric cancer.
Tang Q; Zhang D; Wan M; Jin L
Cancer Biother Radiopharm; 2007 Dec; 22(6):755-61. PubMed ID: 18158766
[TBL] [Abstract][Full Text] [Related]
44. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
Izeradjene K; Douglas L; Delaney A; Houghton JA
Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
[TBL] [Abstract][Full Text] [Related]
45. Mechanism of chronic obstructive uropathy: increased expression of apoptosis-promoting molecules.
Choi YJ; Baranowska-Daca E; Nguyen V; Koji T; Ballantyne CM; Sheikh-Hamad D; Suki WN; Truong LD
Kidney Int; 2000 Oct; 58(4):1481-91. PubMed ID: 11012883
[TBL] [Abstract][Full Text] [Related]
46. Increased bax expression is associated with cell death induced by ganciclovir in a herpes thymidine kinase gene-expressing glioma cell line.
Craperi D; Vicat JM; Nissou MF; Mathieu J; Baudier J; Benabid AL; Verna JM
Hum Gene Ther; 1999 Mar; 10(4):679-88. PubMed ID: 10094211
[TBL] [Abstract][Full Text] [Related]
47. Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1).
Chopin V; Slomianny C; Hondermarck H; Le Bourhis X
Exp Cell Res; 2004 Aug; 298(2):560-73. PubMed ID: 15265702
[TBL] [Abstract][Full Text] [Related]
48. Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3.
Wieder T; Essmann F; Prokop A; Schmelz K; Schulze-Osthoff K; Beyaert R; Dörken B; Daniel PT
Blood; 2001 Mar; 97(5):1378-87. PubMed ID: 11222383
[TBL] [Abstract][Full Text] [Related]
49. Role of antiapoptotic proteins in tumor necrosis factor-related apoptosis-inducing ligand and cisplatin-augmented apoptosis.
Kim JH; Ajaz M; Lokshin A; Lee YJ
Clin Cancer Res; 2003 Aug; 9(8):3134-41. PubMed ID: 12912965
[TBL] [Abstract][Full Text] [Related]
50. The C-terminal tails of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas receptors have opposing functions in Fas-associated death domain (FADD) recruitment and can regulate agonist-specific mechanisms of receptor activation.
Thomas LR; Johnson RL; Reed JC; Thorburn A
J Biol Chem; 2004 Dec; 279(50):52479-86. PubMed ID: 15452120
[TBL] [Abstract][Full Text] [Related]
51. The monoclonal antibody 225 activates caspase-8 and induces apoptosis through a tumor necrosis factor receptor family-independent pathway.
Liu B; Fan Z
Oncogene; 2001 Jun; 20(28):3726-34. PubMed ID: 11439335
[TBL] [Abstract][Full Text] [Related]
52. The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand.
Ozoren N; Kim K; Burns TF; Dicker DT; Moscioni AD; El-Deiry WS
Cancer Res; 2000 Nov; 60(22):6259-65. PubMed ID: 11103780
[TBL] [Abstract][Full Text] [Related]
53. Differential ganciclovir-mediated cell killing by glutamine 125 mutants of herpes simplex virus type 1 thymidine kinase.
Drake RR; Wilbert TN; Hinds TA; Gilbert KM
J Biol Chem; 1999 Dec; 274(52):37186-92. PubMed ID: 10601281
[TBL] [Abstract][Full Text] [Related]
54. Direct binding of Fas-associated death domain (FADD) to the tumor necrosis factor-related apoptosis-inducing ligand receptor DR5 is regulated by the death effector domain of FADD.
Thomas LR; Henson A; Reed JC; Salsbury FR; Thorburn A
J Biol Chem; 2004 Jul; 279(31):32780-5. PubMed ID: 15173180
[TBL] [Abstract][Full Text] [Related]
55. Using HSV-TK/GCV suicide gene therapy to inhibit lens epithelial cell proliferation for treatment of posterior capsular opacification.
Jiang YX; Lu Y; Liu TJ; Yang J; Chen Y; Fang YW
Mol Vis; 2011 Jan; 17():291-9. PubMed ID: 21283526
[TBL] [Abstract][Full Text] [Related]
56. Cell cycle control pathways act as conditioning factors for TK/GCV sensitivity in pancreatic cancer cells.
Abate-Daga D; Garcia-Rodríguez L; Sumoy L; Fillat C
Biochim Biophys Acta; 2010 Oct; 1803(10):1175-85. PubMed ID: 20599444
[TBL] [Abstract][Full Text] [Related]
57. Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apotosis in human malignant glioma cells.
Hao C; Beguinot F; Condorelli G; Trencia A; Van Meir EG; Yong VW; Parney IF; Roa WH; Petruk KC
Cancer Res; 2001 Feb; 61(3):1162-70. PubMed ID: 11221847
[TBL] [Abstract][Full Text] [Related]
58. Intravenous RMP-7 increases delivery of ganciclovir into rat brain tumors and enhances the effects of herpes simplex virus thymidine kinase gene therapy.
LeMay DR; Kittaka M; Gordon EM; Gray B; Stins MF; McComb JG; Jovanovic S; Tabrizi P; Weiss MH; Bartus R; Anderson WF; Zlokovic BV
Hum Gene Ther; 1998 May; 9(7):989-95. PubMed ID: 9607410
[TBL] [Abstract][Full Text] [Related]
59. A caspase-8-independent component in TRAIL/Apo-2L-induced cell death in human rhabdomyosarcoma cells.
Petak I; Vernes R; Szucs KS; Anozie M; Izeradjene K; Douglas L; Tillman DM; Phillips DC; Houghton JA
Cell Death Differ; 2003 Jun; 10(6):729-39. PubMed ID: 12761581
[TBL] [Abstract][Full Text] [Related]
60. [Herpes simplex virus type 1 thymidine kinase/ganciclovir (HSV(1)-TK/GCV) system as an effective "in vivo death switch" of live tumor vaccines].
Kang Y; Xu CJ; Liu XS; Wu CQ; Zhong CP; Gu JR
Ai Zheng; 2005 Aug; 24(8):909-14. PubMed ID: 16086864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
